Published in AIDS Weekly, October 10th, 2005
According to a study from the United States, "Cohort studies indicate that starting highly active antiretroviral therapy (HAART) when the CD4+ T-cell count is less than 200 cells/mcL is associated with poor outcomes. These studies have been unable to address how early HAART should be initiated, however."
"This report uses a modeling approach to compare starting HAART at a mean CD4+ T-cell count greater than 350 cells/mcL (early) versus less than 350 cells/mcL but greater than 200 cells/mcL (later).
"A Markov model tracks people with HIV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.